Clinical trials: Treatment Failure
Upper Airway Obstruction, Respiratory Insufficiency
Astral VAPS AutoEPAP Clinical Trial
Patients with chronic respiratory failure such as those associated with Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS), Obstructive Sleep Apnea (OSA) or Neuromuscular Disease (NMD) are…
- Conditions
- Upper Airway Obstruction, Respiratory Insufficiency, Respiratory Failure
- Trial name
- NCT02683772
- Testing
- Astral
- Where
- 5 sites in United States
- Volunteers
- 42 people
- Sponsor
- ResMed
COVID-19
VA CoronavirUs Research and Efficacy Studies-1
The purpose of this study is to determine if treatment with convalescent plasma improves the clinical outcomes of Veterans who are hospitalized and require supplemental oxygen due to COVID-19.
- Trial name
- VACURES-1 (NCT04539275)
- Testing
- Convalescent Plasma
- Where
- 24 sites in United States, Puerto Rico
- Volunteers
- 75 people
- Sponsor
- VA Office of Research and Development
Kidney Transplant Failure and Rejection
Comparison of the Cognitive and Motor Effects of Treatment Between an Immediate- and Extended-release Tacrolimus (Envarsus® XR) Based Immunosuppression Regimen in Kidney Transplant Recipients
The primary objective is to compare the effect of treatment with an immediate-release tacrolimus to an extended-release tacrolimus (i.e., Envarsus® XR) immunosuppressive regimen on cognitive and motor function in kidney…
- Trial name
- NCT03437577
- Testing
- immediate-release tacrolimus, extended release tacrolimus
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Minnesota
Congestive Heart Failure, Cardiac Resynchronization Therapy
TRIAGE-CRT Telemonitoring in Patients With CHF and Indication of CRT-D
This feasibility study will investigate the clinical benefit of the combined use of BIOTRONIK Home Monitoring (HM) and weight and blood pressure (BP) external telemonitoring (ETM) in the follow-up treatment of patients implanted…
- Trial name
- NCT00395642
- Testing
- Kronos LV-T, Lumax HF-T
- Where
- 12 sites in United States
- Volunteers
- 66 people
- Sponsor
- Biotronik, Inc.
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
This randomized phase III trial studies tipifarnib in treating patients with acute myeloid leukemia (AML) in remission. Tipifarnib may stop the growth of cancer cells by blocking the enzymes necessary for their growth.
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00093470
- Testing
- Clinical Observation, Tipifarnib
- Where
- 341 sites in United States, Israel and 1 more
- Volunteers
- 144 people
- Sponsor
- National Cancer Institute (NCI)
TTR-mediated Amyloidosis
A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
The purpose of this study was to evaluate the safety and clinical activity of long-term dosing with revusiran (ALN-TTRSC). Dosing has been discontinued; patients are being followed-up for safety.
- Trial name
- NCT02292186
- Testing
- Revusiran (ALN-TTRSC)
- Where
- 5 sites in United States, Canada and 1 more
- Volunteers
- 25 people
- Sponsor
- Alnylam Pharmaceuticals
Heart Failure
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
This study was to determine early and more chronic changes in concentrations of biomarkers related to mechanisms of action (MOA) and effects of sacubitril/valsartan therapy over a period of 12 months, and correlated these…
- Trial name
- PROVE-HF (NCT02887183)
- Testing
- LCZ696 (sacubitril/valsartan)
- Where
- 77 sites in United States
- Volunteers
- 794 people
- Sponsor
- Novartis Pharmaceuticals
Renal Failure, End Stage Renal Disease
Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis
The main purpose of this study is to compare the Human Acellular Vessel (HAV) with ePTFE grafts when used for hemodialysis access.
- Conditions
- Renal Failure, End Stage Renal Disease, Hemodialysis, Vascular Access
- Trial name
- NCT02644941
- Testing
- Human Acellular Vessel (HAV), ePTFE graft
- Where
- 38 sites in United States, Germany and 4 more
- Volunteers
- 355 people
- Sponsor
- Humacyte, Inc.
End-Stage Renal Disease, Kidney Failure, Chronic
MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008)
MK-2060 is being developed for prevention of thrombotic complications in end-stage renal disease (ESRD). The purpose of this study is to conduct a preliminary evaluation of the safety and tolerability of MK-2060 treatment in…
- Trial name
- NCT05335005
- Testing
- MK-2060
- Where
- 3 sites in United States, Israel and 1 more
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
Psoriatic Arthritis
Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment
The purpose of this study is to compare the safety and efficacy of secukinumab and ustekinumab in patients with active psoriatic arthritis who showed failure to previous TNFα-inhibitor treatment
- Trial name
- AgAIN (NCT04632927)
- Testing
- Secukinumab, Ustekinumab
- Where
- 28 sites in Germany
- Volunteers
- 119 people
- Sponsor
- Novartis Pharmaceuticals
Cardiac Edema
A Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure)
To investigate the plasma drug level, efficacy, and safety of 7-day repeated oral administration of OPC-41061 at 15 mg/day (treatment period 1) and subsequent 7-day repeated administration of OPC-41061 at 15 mg/day or 30 mg/day…
- Trial name
- NCT00544869
- Testing
- OPC-41061 （Tolvaptan)
- Where
- 6 sites in Japan
- Volunteers
- 52 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Heart Failure, Ventricular Dysfunction, Left
Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone
The purpose is to study if HF treatment guided by NTproBNP in addition to clinical symptoms and signs is more effective than treatment guided by clinical symptoms and signs alone in patients with HF and left ventricular systolic…
- Trial name
- NCT00391846
- Testing
- Captopril, Enalapril, Lisinopril
- Where
- 39 sites in Sweden
- Volunteers
- 252 people
- Sponsor
- AstraZeneca
Atopic Dermatitis, Atopic Dermatitis, Unspecified
A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection
The purpose of this study is to learn about the safety and effects of the study medicine called etrasimod for the possible treatment of atopic dermatitis (AD), also called eczema, in adults who have already tried AD treatments…
- Conditions
- Atopic Dermatitis, Atopic Dermatitis, Unspecified, Eczema, Eczema, Atopic
- Trial name
- NCT05732454
- Testing
- etrasimod
- Where
- 74 sites in United States, Canada and 2 more
- Volunteers
- 58 people
- Sponsor
- Pfizer
Kidney Failure, Chronic Therapy; Hemodialysis
A Single Ascending Dose Study of Soluble Ferric Pyrophosphate Administered Intravenously in Healthy Volunteers.
The purpose of this study is to determine the pharmacokinetics of fixed ascending doses of intravenously administered Soluble Ferric Pyrophosphate
- Trial name
- NCT01920854
- Testing
- soluble ferric pyrophosphate
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Rockwell Medical Technologies, Inc.
Heart Failure, Systolic, Diabetes Mellitus, Type 2
Treatment of Diabetes in Patients With Systolic Heart Failure
Investigator Initiated Study to study the effects of Canagliflozin 100 milligrams (mg) vs Sitagliptin 100 mg on parameters of aerobic exercise capacity (peak oxygen consumption [VO2]) and ventilator efficiency (minute ventilation…
- Trial name
- NCT02920918
- Testing
- Canagliflozin, Sitagliptin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Virginia Commonwealth University
Degradation of Top2b and Top2a in Human by Dexrazoxane, Time Course and Degradation of Top2b in Human by Dexrazoxane
Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane
The purpose of this research study is to determine whether early administration of Dexrazoxane prevents Doxorubicin induced cardiotoxicity.
- Conditions
- Degradation of Top2b and Top2a in Human by Dexrazoxane, Time Course and Degradation of Top2b in Human by Dexrazoxane, Effects of Dexrazoxane on Healthy Human
- Trial name
- PHOENIX1 (NCT03930680)
- Testing
- Dexrazoxane
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Sudden Cardiac Death, Heart Failure
Educational Videos to Address Racial Disparities in Implantable Cardioverter Defibrillator Therapy
VIVID is a prospective, multicenter, randomized clinical trial in African American patients that will to evaluate: (1) the effect of an educational video on knowledge of sudden cardiac death (SCD) and implantable cardioverter…
- Trial name
- VIVID (NCT02819973)
- Testing
- Educational Video1, Educational Video 2, Usual Care 3
- Where
- 14 sites in United States
- Volunteers
- 343 people
- Sponsor
- Duke University
Growth Failure, X-linked Severe Combined Immunodeficiency (XSCID)
Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1
This study will evaluate the safety and effectiveness of insulin-like growth factor-1 (IGF-1) to treat patients with X-linked severe combined immunodeficiency (XSCID).
- Conditions
- Growth Failure, X-linked Severe Combined Immunodeficiency (XSCID), Growth Hormone Resistence
- Trial name
- NCT00490100
- Testing
- Increlex
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Heart Failure
Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure
The primary objective of this study is to test the hypothesis that high-dose spironolactone will lead to greater proportional reduction in NT-proBNP levels from randomization to 96 hours over standard of care.
- Trial name
- ATHENA-HF (NCT02235077)
- Testing
- Spironolactone
- Where
- 22 sites in United States
- Volunteers
- 360 people
- Sponsor
- Duke University
End Stage Renal Disease
Treatment Modification to Reduce Symptom Burden in Hemodialysis
Many patients on hemodialysis experience high rates of symptom burden, such as pain, depression, anxiety and difficulty breathing.
- Trial name
- NCT01775800
- Testing
- Treatment modification
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- The Rogosin Institute